Health Economics›Waldenstroem macroglobulinemia›First-line therapy non-randomized or retrospective data

First-line therapy non-randomized or retrospective data

Waldenstroem macroglobulinemia · 12 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Thalidomide and Rituximab Variant #01	—	R 152 755	28d	—	—	—	—	—
CaRD Variant #02	—	R 124 309	21d	—	—	—	—	—
Fludarabine and Rituximab (FR) Variant #06	—	R 117 749	28d	—	—	—	—	—
IDR Variant #01	—	R 89 513	56d	—	—	—	—	—
FCR Variant #09	—	R 70 417	28d	~56.4 mo	—	~62	~R 4 365 849 PFS proxy · indirect	10
Bortezomib and Rituximab (VR) Variant #06	—	R 64 235	35d	~12.8 mo	—	~12	~R 770 814 PFS proxy · indirect	1
Cladribine and Rituximab Variant #01	—	R 33 968	21d	—	—	—	—	—
BDR Variant #02	—	R 32 826	84d	—	—	—	—	—
Everolimus monotherapy Variant #01	—	R 18 360	28d	~6.0 mo	~18.1 mo	~7	~R 128 518 PFS proxy · indirect	15
Fludarabine monotherapy Variant #01	—	R 11 691	28d	~16.5 mo	~52.9 mo	~18	~R 210 435 PFS proxy · indirect	4
Thioguanine monotherapy Variant #01	—	R 6 994	28d	—	—	—	—	—
PCR N/A - secondary systemic drug Partial	—	R 172	28d	—	—	—	—	—

12 of 12 regimens shown